09:12:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Nanexa är ett drug delivery-bolag med en egenutvecklad och patenterad drug delivery plattform PharmaShell® som används för formulering av injicerbara depåläkemedel som skapar en tillförsel av läkemedel till blodet. PharmaShell processen baseras på ALD (Atomic Layer Deposition) teknologin som innesluter läkemedelspartiklar med ett tunt skal och skapar möjlighet för läkemedelsbolag att utveckla helt nya läkemedelsprodukter. Nanexa har idag samarbete med flertalet läkemedelsbolag.

Kalender

2023-02-16 Bokslutskommuniké 2022
2022-10-25 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-06-09 Årsstämma 2022
2022-04-20 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning NANEXA 0.00 SEK
2021-02-18 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-03 Ordinarie utdelning NANEXA 0.00 SEK
2020-06-02 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-12 Ordinarie utdelning NANEXA 0.00 SEK
2019-06-11 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-12 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning NANEXA 0.00 SEK
2018-05-29 Årsstämma 2018
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-10-23 Extra Bolagsstämma 2017
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-13 Ordinarie utdelning NANEXA 0.00 SEK
2017-06-12 Årsstämma 2017
2017-05-17 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-27 Ordinarie utdelning NANEXA 0.00 SEK
2016-05-26 Årsstämma 2016
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-06 Extra Bolagsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-11-19 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2021-05-24 16:05:00

On May 24, 2021, the Annual General Meeting of Nanexa AB (publ) was held. Due to the risk of spreading of Covid-19 and the authorities' regulations and advice, the Annual General Meeting was held only through advance voting (so-called postal voting) in accordance with temporary rules.

At the meeting, it was decided to approve the presented income statement and balance sheet. At the meeting, it was also decided to carry forward the company's results in accordance with the Board's proposal in the annual report.

The Annual General Meeting resolved to discharge the board members and the CEO from liability.

At the meeting, it was decided that board fees shall be paid in the amount of SEK 260,000 to the Chairman of the Board, in the amount of SEK 230,000 to the Chairman of the Audit Committee and in the amount of SEK 130,000 each to other Board members who are not employees of the company. Furthermore, it was decided that auditors' fees shall be paid according to approved invoices.

The Annual General Meeting resolved to re-elect Göran Ando, ​​Bengt Gustavsson, Urban Paulsson, Mårten Rooth, Otto Skolling and Magnus Westgren and to elect Birgit Stattin Norinder and Eva Nilsagård as new Board members. Göran Ando was re-elected Chairman of the Board.

Öhrlings PricewaterhouseCoopers AB was appointed auditor. Niclas Bergenmo will take over as chief auditor after Lars Kylberg.

It was resolved to establish a Nomination Committee prior to the 2022 Annual General Meeting and to establish instructions for the Nomination Committee in accordance with the proposal included in the notice convening the Annual General Meeting.

In accordance with the Board's proposal, it was resolved to change the wording of the Articles of Association's provisions regarding share capital (§ 4) and number of shares (§ 5).

The Annual General Meeting resolved to adopt the Board's proposals for authorizations for the Board to decide on rights issue and directed issue of shares respectively.

Finally, in accordance with the Board's proposal, the Annual General Meeting resolved to establish a warrant-based incentive program covering all employees in the company. However, the Nomination Committee's proposal to establish a warrant-based incentive program including some of the Board members did not receive the required majority.

The content of the resolutions is stated (in Swedish) in the Notice of the Annual General Meeting (Kallelse till Årsstämma).